ArticleRadiology and oncology2026
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: a single-institution experience.
Article in Radiology and oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeritoneal metastases (PM) from colorectal cancer are associated with poor prognosis. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has been proposed for selected patients, although its role remains debated. This study evaluates the efficacy and safety of CRS plus HIPEC in a single institution. PATIENTS AND
methodsThis retrospective study included patients with colorectal PM treated with CRS and HIPEC between 2009 and 2024. Preoperative staging involved CT and/or MRI, and all cases were discussed in a multidisciplinary team. Disease burden was assessed using the Peritoneal Cancer Index (PCI), and completeness of cytoreduction (CC score) was recorded. HIPEC was performed with oxaliplatin (360 mg/m
resultsFifty patients (mean age 54 years) were included. Complete cytoreduction (CC-0/1) was achieved in 88% of cases, with a median PCI of 8.33. Severe complications occurred in 18% of patients, with no 30-day mortality. After a median follow-up of 34 months, median OS was 49 months; 1- and 5-year OS rates were 96% and 54%, respectively. Median DFS was 14 months. PCI, CC score, and prior surgical score (PSS) were associated with OS on univariate analysis, while PCI and CC score remained independent prognostic factors.
conclusionsCRS plus HIPEC is a feasible and effective treatment for selected patients with colorectal PM, with acceptable morbidity. Low PCI and complete cytoreduction are key predictors of improved survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.